Clinical Professor
Head, Division of Endocrinology
University of British Columbia, 1986, MD
University of British Columbia, 1991, Internal Medicine Residency
University of British Columbia, 1992, Endocrinology Fellowship
University of British Columbia, 1982, PhD, (Physiology)
Research Interests

See Dr. Dahl’s publications here

1. Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P; CNODES Investigators. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. N Engl J Med. 2016 Mar 24;374(12):1145-54.

2. Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Juurlink DN, Targownik LE, Turin TC, Paterson JM, Ernst P; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016 Feb 17;352:i581. doi: 10.1136/bmj.i581.

3. Harris D, Barts A, Connors J, Dahl M, Elliott T, Kong J, Keane T, Thompson D, Stafford S, Ur E, Sirrs S. Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol. 2013 Dec;20(6):e532-8.

4. Cameron, C, Virani A Dean H, Evans M,Dolovich L, Dahl M Utilization and Expenditure on Blood Glucose Test Strips in Canada. Canadian Journal of Diabetes. 2010; 34 (1):34-40.

5. McIntosh B, Yu C, Lal A, Chelak K, Cameron C, Singh S, Dahl M  Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis.  Open Medicine 2010;4(2):e102.

6. Dahl M, Feldman J, Goldberg JM, Jaberi A Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism  2006; Vol 9 Issue: ¾, p111-134.

Gordon and Leslie Diamond Centre Room 4145
2775 Laurel St.
Vancouver, BC V5Z 1M9
phone: 6048755577
fax: 6048755188